VanEck Associates’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-180,471
| Closed | -$21.8M | – | 1481 |
|
|
2023
Q1 | $21.8M | Buy |
180,471
+21,734
| +14% | +$2.63M | 0.05% | 230 |
|
|
2022
Q4 | $18.2M | Buy |
158,737
+1,613
| +1% | +$185K | 0.05% | 254 |
|
|
2022
Q3 | $15.9M | Buy |
157,124
+22,897
| +17% | +$2.32M | 0.05% | 254 |
|
|
2022
Q2 | $13.6M | Buy |
134,227
+20,057
| +18% | +$2.03M | 0.04% | 282 |
|
|
2022
Q1 | $13.3M | Sell |
114,170
-6,400
| -5% | -$745K | 0.03% | 312 |
|
|
2021
Q4 | $13.8M | Buy |
+120,570
| New | +$13.8M | 0.03% | 310 |
|
|
2020
Q4 | – | Sell |
-95,036
| Closed | -$10.6M | – | 1046 |
|
|
2020
Q3 | $10.6M | Buy |
+95,036
| New | +$10.6M | 0.03% | 254 |
|